Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$23.54 USD

23.54
12,327,695

+1.04 (4.62%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $23.53 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Zacks Equity Research

Here's Why You Should Consider Betting on CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

HealthEquity Acquires WageWorks, To Make Notable Investments

by Zacks Equity Research

HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.

Zacks Equity Research

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

Zacks Equity Research

Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe

by Zacks Equity Research

With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.

Zacks Equity Research

What's in the Cards for HealthEquity (HQY) in Q2 Earnings?

by Zacks Equity Research

Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.

Zacks Equity Research

Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.

Zacks Equity Research

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

by Zacks Equity Research

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

Zacks Equity Research

Patterson Companies (PDCO) Earnings Beat Estimates in Q1

by Zacks Equity Research

Patterson Companies' (PDCO) Q1 results benefit from higher revenues, gross margin expansion, solid show by Corporate segment and lower expenses.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Equity Research

Varian's ProBeam Compact System Picked by University of Miami

by Zacks Equity Research

Varian (VAR) sees notable developments in its Proton Solutions business of late.

Zacks Equity Research

Henry Schein Expands SolutionsHub With CueSquared MobilePay

by Zacks Equity Research

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Zacks Equity Research

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Zacks Equity Research

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.

Zacks Equity Research

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

Zacks Equity Research

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Zacks Equity Research

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.

Zacks Equity Research

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Zacks Equity Research

Medtronic (MDT) Benefits from Strength Across Business Groups

by Zacks Equity Research

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Zacks Equity Research

Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost

by Zacks Equity Research

In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.

Zacks Equity Research

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Zacks Equity Research

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Zacks Equity Research

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.